Real‐World Use of Semaglutide for Weight Management: Dose Titration, Discontinuation Patterns and Weight Changes
Authors' conclusion
Based on the experience from utilisation in a single general practise, semaglutide for weight management is frequently discontinued and titrated slower and to lower maintenance doses in real-world clinical practise than in the approved labelling. Despite this, the observed mean weight loss for individuals who had not discontinued treatment was substantial.
Study context
- Population
- Adults with overweight or obesity prescribed semaglutide for weight management, Dec 2022–May 2024, one general practice in Denmark; 76% women, mean age 48 years (SD 13), mean baseline weight 105 kg (SD 23.8)
- Participants
- 206 adults
- Outcome
- Relative mean change in body weight in individuals who had not discontinued treatment and had baseline and follow-up weight
- Follow-up
- Baseline to 12 months
Methodological detailssingle general practice, primary care
- Single general practice
- Primary care
Main finding
As reported in the abstract
Relative mean change in body weight, in those who had not discontinued treatment · 12 months
Relative mean body weight change after 12 months
−13.6 (95% CI −15.0 to −12.2)%
Observational data: associations, not effects.
Further findings
Treatment status · 12 months
- Permanently discontinued semaglutide
- 38% (n = 78)
- Temporarily discontinued (paused)
- 15% (n = 30)
- Remained on treatment
- 48% (n = 98)
Maintenance dose among those remaining on treatment · 12 months
- ≤ 1.0 mg/week
- 40%
- 1.7 mg/week
- 30%
- 2.4 mg/week
- 30%
Original publication
Real‐World Use of Semaglutide for Weight Management: Dose Titration, Discontinuation Patterns and Weight Changes. Diabetes Obes Metab. Published 8 July 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →